1. In Vivo
  2. >>Innovation

BioInvent Using New Screening Platforms To Identify Novel IO Targets

Biotech Boasts Five Compounds Being Examined Across Six Studies

 
• By Chloe Kent

Swedish biotech BioInvent uses its extensive antibody library to identify new immuno-oncology targets and translate these into therapies. Following the delivery of some impressive early-stage research at the annual Society for Immunotherapy for Cancer conference, CEO Martin Welschof caught up with In Vivo to share more about the firm’s story so far.

Curving shelf of books in public library
BioInvent has an extensive antibody library of more than 30 billion human antibody genes • Source: Shutterstock

At Swedish biotech BioInvent, early-stage data on two anti-tumor necrosis factor receptor 2 (TNFR2) antibodies are starting to show promise. Presenting at the annual Society for Immunotherapy for Cancer conference, BioInvent was able to reveal that its candidates BI-1910 and BI-1808 both demonstrated anticancer effects in recent studies.

BI-1910 indicated broad anti-tumor activity in preclinical studies, activating T-cells and natural killer cells and showing anti-tumor activity independent of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

Novo Nordisk Foundation Brings World’s Most Powerful Computer To Nordics

 
• By David Wild

Denmark’s €80m QuNorth project, co-led by the Novo Nordisk Foundation, launches most powerful quantum computer to advance drug discovery and broader scientific research across the Nordics.

Rising Leaders 2025: Daniel Cohen’s Transition From Grad To AI Pioneer In Drug Discovery

 
• By David Wild

A 25-year-old's “naive optimism” becomes the driving force behind one of biopharma's most ambitious AI ventures.

How Blood-Based Biomarkers Are Transforming Alzheimer’s Clinical Research And Patient Care

 
• By Nick Culshaw 

Blood-based biomarkers are revolutionizing Alzheimer’s diagnosis by enabling earlier, more accessible, and less invasive detection, which is accelerating clinical research and improving patient care outcomes.

Enabling Precision Medicine At Scale Through Digital Innovation And AI

 
• By Cristal Thompson and Justyna Anna Lisowska

AI is reshaping clinical trials by enabling precision medicine, accelerating patient stratification, optimizing trial design, and transforming complex data into actionable insights for faster, more effective drug development.

More from In Vivo

Enabling Precision Medicine At Scale Through Digital Innovation And AI

 
• By Cristal Thompson and Justyna Anna Lisowska

AI is reshaping clinical trials by enabling precision medicine, accelerating patient stratification, optimizing trial design, and transforming complex data into actionable insights for faster, more effective drug development.

J&J Challenges Medtronic At The Top Of Medtech Rankings

 
• By Ashley Yeo

Medtronic held its grip on first place in the 2024 global medical device and diagnostics rankings after losing it two years ago to Abbott, which is now in third place behind fast-rising, acquisitive Johnson & Johnson MedTech.

‘By Most Measures A Failure’: Ten Years On From Teva-Actavis

 
• By Dean Rudge

A decade after Teva’s $40.5bn acquisition of Actavis Generics, the deal remains a defining moment for the company. This retrospective explores Teva’s hopes, consequences, leadership shifts, and the firm’s new growth strategy under CEO Richard Francis.